K Martijn Akkerhuis

List of Publications by Citations

62 papers	1,232 citations	19 h-index	34 g-index
66 ext. papers	1,557 ext. citations	4.8 avg, IF	3.95 L-index

#	Paper	IF	Citations
62	In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. *European Heart Journal*, **2014**, 35, 639-47	9.5	234
61	PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. *Atherosclerosis*, **2016**, 248, 117-22	3.1	96
60	Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. *Atherosclerosis*, **2015**, 243, 560-6	3.1	86
59	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. *Journal of the American College of Cardiology*, **2017**, 70, 2378-2388	15.1	72
58	Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. *Journal of Lipid Research*, **2018**, 59, 1729-1737	6.3	64
57	Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up. *European Heart Journal*, **2018**, 39, 295-302	9.5	60
56	CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study. *Journal of Cardiovascular Translational Research*, **2016**, 9, 302-14	3.3	42
55	Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. *European Journal of Heart Failure*, **2018**, 20, 89-96	12.3	41
54	Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS study). *American Journal of Cardiology*, **2014**, 114, 1497-503	3	38
53	Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis. *International Journal of Cardiology*, **2015**, 181, 425-9	3.2	37
52	Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: results from the ATHEROREMO-IVUS study. *Atherosclerosis*, **2014**, 236, 18-24	3.1	30
51	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. *JACC: Cardiovascular Interventions*, **2018**, 11, 1576-1586	5	28
50	Antibodies to periodontal pathogens are associated with coronary plaque remodeling but not with vulnerability or burden. *Atherosclerosis*, **2014**, 237, 84-91	3.1	27
49	Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. *American Heart Journal*, **2018**, 196, 36-48	4.9	26
48	Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study. *International Journal of Cardiology*, **2017**, 235, 124-132	3.2	23
47	Prognostic Value of Intravascular Ultrasound in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*, **2018**, 72, 2003-2011	15.1	23
46	Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. *Kidney International*, **2018**, 93, 952-960	9.9	21

45	High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome. *Circulation*, **2019**, 139, 134-136	16.7	19
44	Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. *Circulation*, **2018**, 138, 646-648	16.7	19
43	A simple risk chart for initial risk assessment of 30-day mortality in patients with cardiogenic shock from ST-elevation myocardial infarction. *European Heart Journal: Acute Cardiovascular Care*, **2016**, 5, 101-7	4.3	18
42	Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study). *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3954-3964	5.6	18
41	Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. *Journal of the American Heart Association*, **2017**, 6,	6	17
40	IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). *EBioMedicine*, **2018**, 36, 63-72	8.8	15
39	Short- and Long-term Prognosis of Patients With Acute Heart Failure With and Without Diabetes: Changes Over the Last Three Decades. *Diabetes Care*, **2018**, 41, 143-149	14.6	14
38	Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome-a prospective multicentre biomarker study conducted in the Netherlands. *BMJ Open*, **2016**, 6, e012929	3	14
37	Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography. *Coronary Artery Disease*, **2017**, 28, 23-32	1.4	13
36	Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study. *International Journal of Cardiology*, **2014**, 177, 847-53	3.2	13
35	Smoking in Relation to Coronary Atherosclerotic Plaque Burden, Volume and Composition on Intravascular Ultrasound. *PLoS ONE*, **2015**, 10, e0141093	3.7	12
34	Utility of temporal profiles of new cardio-renal and pulmonary candidate biomarkers in chronic heart failure. *International Journal of Cardiology*, **2019**, 276, 157-165	3.2	11
33	Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. *Journal of the American Heart Association*, **2016**, 5, e002688	6	10
32	Temporal patterns of macrophage- and neutrophil-related markers are associated with clinical outcome in heart failure patients. *ESC Heart Failure*, **2020**, 7, 1190-1200	3.7	8
31	Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study). *Atherosclerosis*, **2016**, 254, 20-27	3.1	8
30	Renal function and anemia in relation to short- and long-term prognosis of patients with acute heart failure in the period 1985-2008: A clinical cohort study. *PLoS ONE*, **2018**, 13, e0201714	3.7	7
29	Associations of 26 Circulating Inflammatory and Renal Biomarkers with Near-Infrared Spectroscopy and Long-term Cardiovascular Outcome in Patients Undergoing Coronary Angiography (ATHEROREMO-NIRS Substudy). *Current Atherosclerosis Reports*, **2018**, 20, 52	6	7
28	Temporal Pattern of Growth Differentiation Factor-15 Protein After Acute Coronary Syndrome (From the BIOMArCS Study). *American Journal of Cardiology*, **2019**, 124, 8-13	3	6

27	Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 2099-2106	5.9	6
26	Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS. *Data in Brief*, **2019**, 27, 104750	1.2	6
25	Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bio-SHiFT study). *Clinical Cardiology*, **2020**, 43, 630-638	3.3	6
24	The temporal pattern of immune and inflammatory proteins prior to a recurrent coronary event in post-acute coronary syndrome patients. *Biomarkers*, **2019**, 24, 199-205	2.6	5
23	Impact of Relative Conditional Survival Estimates on Patient Prognosis After Percutaneous Coronary Intervention. *Circulation: Cardiovascular Quality and Outcomes*, **2017**, 10,	5.8	4
22	SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease. *PLoS ONE*, **2018**, 13, e0200076	3.7	4
21	Adiponectin in Relation to Coronary Plaque Characteristics on Radiofrequency Intravascular Ultrasound and Cardiovascular Outcome. *Arquivos Brasileiros De Cardiologia*, **2018**, 111, 345-353	1.2	3
20	Longitudinal patterns of N-terminal pro B-type natriuretic peptide, troponin T, and C-reactive protein in relation to the dynamics of echocardiographic parameters in heart failure patients. *European Heart Journal Cardiovascular Imaging*, **2020**, 21, 1005-1012	4.1	3
19	Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission. *American Heart Journal*, **2019**, 216, 143-146	4.9	2
18	Repeated Echocardiograms Do Not Provide Incremental Prognostic Value to Single Echocardiographic Assessment in Minimally Symptomatic Patients with Chronic Heart Failure: Results of the Bio-SHiFT Study. *Journal of the American Society of Echocardiography*, **2019**, 32, 1000-1009	5.8	2
17	Left ventricular remodelling and prognosis after discharge in new-onset acute heart failure with reduced ejection fraction. *ESC Heart Failure*, **2021**, 8, 2679-2689	3.7	2
16	Long-Term Follow-Up of the Randomized (BIOMArCS-2) Glucose Trial: Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome. *Circulation*, **2016**, 134, 984-6	16.7	2
15	Real-Life Use of Neurohormonal Antagonists and Loop Diuretics in Chronic Heart Failure: Analysis of Serial Biomarker Measurements and Clinical Outcome. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 346-355	6.1	2
14	Response to Letter to the Editor: "Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study)". *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 736-737	5.6	1
13	Evaluation of 42 cytokines, chemokines and growth factors for prediction of cardiovascular outcome in patients with coronary artery disease. *International Journal of Cardiology*, **2015**, 184, 724-727	3.2	1
12	Comparison of temporal changes in established cardiovascular biomarkers after acute coronary syndrome between Caucasian and Chinese patients with diabetes mellitus. *Biomarkers*, **2020**, 25, 341-348	2.6	1
11	Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. *Biomarkers in Medicine*, **2021**, 15, 247-255	2.3	1
10	Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease. *International Journal of Cardiology*, **2016**, 221, 682-7	3.2	1

9	Evolution of renal function and predictive value of serial renal assessments among patients with acute coronary syndrome: BIOMArCS study. *International Journal of Cardiology*, **2020**, 299, 12-19	3.2	1
8	A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. *BMC Medicine*, **2021**, 19, 21	11.4	1
7	Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study).. *Scientific Reports*, **2022**, 12, 2795	4.9	1
6	High-frequency metabolite profiling and the incidence of recurrent cardiac events in patients with post-acute coronary syndrome. *Biomarkers*, **2020**, 25, 235-240	2.6	0
5	Development and validation of a risk model for long-term mortality after percutaneous coronary intervention: The IDEA-BIO Study. *Catheterization and Cardiovascular Interventions*, **2018**, 91, 686-695	2.7	0
4	Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events.. *Biomarkers*, **2022**, 1-17	2.6	0
3	IGF-1 is not related to long-term outcome in hyperglycemic acute coronary syndrome patients. *Diabetes and Vascular Disease Research*, **2021**, 18, 14791641211047436	3.3	0
2	Serially Measured Cytokines and Cytokine Receptors in Relation to Clinical Outcome in Patients With Stable Heart Failure. *Canadian Journal of Cardiology*, **2020**, 36, 1587-1591	3.8	0
1	Response: Serial blood biomarker measurements for elucidation of the pathophysiology of heart failure. *International Journal of Cardiology*, **2019**, 278, 266	3.2	